USD 1.82
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| ALLO | -1.1 | -11.2 | -1.1 | -35.9 | -35.7 | -41.1 | -84.4 | -92.9 | -92.7 | -92.7 |
| S&P 500 | 1.0 | 3.7 | 2.2 | 2.3 | 8.9 | 23.9 | 32.3 | 80.6 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | ALLO |
| name | Allogene Therapeutics, Inc. |
| price | 1.82 |
| changes percentage | -1.087 |
| change | -0.02 |
| day low | 1.785 |
| day high | 1.9 |
| year high | 5.78 |
| year low | 1.78 |
| market cap | 381603040 |
| price avg 50 | 2.2898 |
| price avg 200 | 2.6539 |
| exchange | NASDAQ |
| volume | 2143425 |
| avg volume | 2698240 |
| open | 1.87 |
| previous close | 1.84 |
| eps | -1.55 |
| pe | -1.17 |
| earnings announcement | 2025-03-12T10:59:00.000+0000 |
| shares outstanding | 209672000 |
| timestamp | 2025-01-17 21:00:01 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001737287 | |||
| revenue | 95000 | 243000 | -60.91 |
| gross profit | -242819000 | -16485000 | -1372.97 |
| gross profit ratio | -2555.99 | -67.84 | -3667.70 |
| research and development expenses | 242914000 | 256387000 | -5.25 |
| operating expenses | 327832000 | 335692000 | -2.34 |
| interest income | 18307000 | 4566000 | 300.94 |
| interest expense | 0 | 0 | NaN |
| ebitda | -300293000 | -321241000 | 6.52 |
| ebitdaratio | -3160.98 | -1380.45 | -128.98 |
| operating income | -327737000 | -335449000 | 2.30 |
| operating income ratio | -3449.86 | -1380.45 | -149.91 |
| net income | -327265000 | -329815000 | 0.77 |
| net income ratio | -3444.89 | -1357.26 | -153.81 |
| eps | -2.09 | -2.3 | 9.13 |
Revenue Growth: revenue increased to 0 million in 2023 from 0 million in 2022 representing a change of -60.91%. This indicates a sales growth, which is a positive sign for the company.
Operating Expenses: Operating Expenses decreased to 328 million in 2023 from 336 million in 2022 representing a change of -2.34%. The decrease in operating expenses can be attributed to various factors such as improved profitability, cost optimization and financial stability, lower operating expenses can be positive indicators.
Earnings per Share (EPS): EPS increased to -2.09 in 2023 from -2.09 in 2022 representing a change of 9.13%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Gross Profit: Gross Profit decreased to -243 million in 2023 from -16 million in 2022 representing a change of -1372.97%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 243 million in 2023 from 256 million in 2022 representing a change of -5.25%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -300 million in 2023 from -321 million in 2022 representing a change of 6.52%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -328 million in 2023 from -335 million in 2022 representing a change of 2.3%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -327 million in 2023 from -330 million in 2022 representing a change of 0.77%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001737287 | |||
| revenue | 0 | 0 | NaN |
| gross profit | 0 | -3644000 | 100.00 |
| gross profit ratio | 0 | 0 | NaN |
| research and development expenses | 44713000 | 46711000 | -4.28 |
| operating expenses | 71774000 | 62798000 | 14.29 |
| interest income | 6705000 | 4988000 | 34.42 |
| interest expense | 100000 | 0 | NaN |
| ebitda | -62986000 | -62798000 | -0.30 |
| ebitdaratio | 0 | 0 | NaN |
| operating income | -71774000 | -66441999 | -8.03 |
| operating income ratio | 0 | 0 | NaN |
| net income | -66293000 | -66358000 | 0.10 |
| net income ratio | 0 | 0 | NaN |
| eps | -0.32 | -0.35 | 8.57 |
Gross Profit: Gross Profit increased to 0 million in 2024Q3 from -4 million in 2024Q2 representing a change of 100.0%. This indicates a sales profitability growth, which is a positive sign for the company.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -63 million in 2024Q3 from -63 million in 2024Q2 representing a change of -0.3%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -72 million in 2024Q3 from -66 million in 2024Q2 representing a change of -8.03%. The increase in operating income indicates better operational performance and increased profitability.
Earnings per Share (EPS): EPS increased to -0.32 in 2024Q3 from -0.32 in 2024Q2 representing a change of 8.57%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 45 million in 2024Q3 from 47 million in 2024Q2 representing a change of -4.28%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 72 million in 2024Q3 from 63 million in 2024Q2 representing a change of 14.29%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Net Income: Net income decreased to -66 million in 2024Q3 from -66 million in 2024Q2 representing a change of 0.1%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001737287 | |||
| total assets | 642837000 | 817079000 | -21.32 |
| total liabilities | 130604000 | 151209000 | -13.63 |
| total equity | 512233000 | 665870000 | -23.07 |
| cash and cash equivalents | 83155000 | 576471000 | -85.58 |
| short term investments | 365542000 | 455416000 | -19.73 |
| long term investments | 3645000 | 59151000 | -93.84 |
| total current assets | 459115000 | 528824000 | -13.18 |
| total non current assets | 183722000 | 288255000 | -36.26 |
| total current liabilities | 37079000 | 54518000 | -31.99 |
| total non current liabilities | 93525000 | 96691000 | -3.27 |
| common stock | 169000 | 144000 | 17.36 |
| retained earnings | -1562233000 | -1235980000 | -26.40 |
| total debt | 95121000 | 95122000 | -0.00 |
Total Assets: Total Assets decreased to 643 million in 2023 from 817 million in 2022 representing a change of -21.32%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 512 million in 2023 from 666 million in 2022 representing a change of -23.07%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 83 million in 2023 from 576 million in 2022 representing a change of -85.58%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 366 million in 2023 from 455 million in 2022 representing a change of -19.73%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 459 million in 2023 from 529 million in 2022 representing a change of -13.18%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,562 million in 2023 from -1,236 million in 2022 representing a change of -26.4%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 131 million in 2023 from 151 million in 2022 representing a change of -13.63%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 37 million in 2023 from 55 million in 2022 representing a change of -31.99%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2023 from 0 in 2022 representing a change of 17.36%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 95 million in 2023 from 95 million in 2022 representing a change of -0.0%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001737287 | |||
| total assets | 589120000 | 646883000 | -8.93 |
| total liabilities | 125372000 | 131845000 | -4.91 |
| total equity | 463748000 | 515038000 | -9.96 |
| cash and cash equivalents | 51239000 | 170667000 | -69.98 |
| short term investments | 240325000 | 273961000 | -12.28 |
| long term investments | 111821000 | 11426000 | 878.65 |
| total current assets | 304415000 | 457124000 | -33.41 |
| total non current assets | 284705000 | 189759000 | 50.04 |
| total current liabilities | 32571000 | 37305000 | -12.69 |
| total non current liabilities | 92801000 | 94539999 | -1.84 |
| common stock | 210000 | 209000 | 0.48 |
| retained earnings | -1759884000 | -1693591000 | -3.91 |
| total debt | 85135000 | 94210000 | -9.63 |
Total Assets: Total Assets decreased to 589 million in 2024Q3 from 647 million in 2024Q2 representing a change of -8.93%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 464 million in 2024Q3 from 515 million in 2024Q2 representing a change of -9.96%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 51 million in 2024Q3 from 171 million in 2024Q2 representing a change of -69.98%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 240 million in 2024Q3 from 274 million in 2024Q2 representing a change of -12.28%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 304 million in 2024Q3 from 457 million in 2024Q2 representing a change of -33.41%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -1,760 million in 2024Q3 from -1,694 million in 2024Q2 representing a change of -3.91%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 125 million in 2024Q3 from 132 million in 2024Q2 representing a change of -4.91%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 33 million in 2024Q3 from 37 million in 2024Q2 representing a change of -12.69%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 0 in 2024Q3 from 0 in 2024Q2 representing a change of 0.48%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 85 million in 2024Q3 from 94 million in 2024Q2 representing a change of -9.63%. This indicates a reduction in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001737287 | |||
| net change in cash | 21251000 | -111410000 | 119.07 |
| operating cash flow | -237733000 | -220519000 | -7.81 |
| free cash flow | -239249000 | -225710000 | -6.00 |
| capital expenditure | -1516000 | -5191000 | 70.80 |
| depreciation and amortization | 14199000 | 14295000 | -0.67 |
| deferred income tax | 0 | 8079000 | -100.00 |
| stock based compensation | 65951000 | 83600000 | -21.11 |
| accounts payables | -7502000 | 4868000 | -254.11 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | -111350000 | 100.00 |
| investments in property plant and equipment | -1516000 | -5191000 | 70.80 |
| net cash used for investing activites | 163289000 | 106159000 | 53.82 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 91112000 | 2950000 | 2988.54 |
| common stock repurchased | 0 | 2461000 | -100.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 95695000 | 2950000 | 3143.90 |
| cash at end of period | 93447000 | 72196000 | 29.44 |
| accounts receivables | 0 | 0 | NaN |
| cash at beginning of period | 72196000 | 183606000 | -60.68 |
Net Change in Cash: Net Change in Cash increased to 21 million in 2023 from -111 million in 2022 representing a change of 119.07%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Stock-Based Compensation: Stock-Based Compensation decreased to 66 million in 2023 from 84 million in 2022 representing a change of -21.11%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Operating Cash Flow: Operating Cash Flow decreased to -238 million in 2023 from -221 million in 2022 representing a change of -7.81%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -239 million in 2023 from -226 million in 2022 representing a change of -6.0%. This indicates a decrease in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure increased to -2 million in 2023 from -5 million in 2022 representing a change of 70.8%. This indicates an increase in the cash outflow required for acquiring or improving long-term assets.
Accounts Payables: The absolute value of Accounts Payables increased to 8 million in 2023 from 5 million in 2022 representing a change of -254.11%. This indicates that the company has increased its outstanding obligations to its suppliers.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001737287 | |||
| operating cash flow | -44115000 | -63588000 | 30.62 |
| free cash flow | -44544000 | -63588000 | 29.95 |
| capital expenditure | -429000 | 0 | NaN |
| depreciation and amortization | 3207000 | 3644000 | -11.99 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 13387000 | 13559000 | -1.27 |
| accounts receivables | 0 | 0 | NaN |
| accounts payables | -7227000 | 6808000 | -206.15 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -429000 | 0 | NaN |
| net cash used for investing activites | -75992000 | 74613000 | -201.85 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -106952000 | 106323000 | -200.59 |
| common stock repurchased | 679000 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 679000 | 108603000 | -99.37 |
| net change in cash | -119428000 | 119628000 | -199.83 |
| cash at end of period | 61531000 | 170667000 | -63.95 |
| cash at beginning of period | 180959000 | 51039000 | 254.55 |
Net Change in Cash: Net Change in Cash decreased to -119 million in 2024Q3 from 120 million in 2024Q2 representing a change of -199.83%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Accounts Payables: The absolute value of Accounts Payables increased to 7 million in 2024Q3 from 7 million in 2024Q2 representing a change of -206.15%. This indicates that the company has increased its outstanding obligations to its suppliers.
Operating Cash Flow: Operating Cash Flow increased to -44 million in 2024Q3 from -64 million in 2024Q2 representing a change of 30.62%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to -45 million in 2024Q3 from -64 million in 2024Q2 representing a change of 29.95%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 13 million in 2024Q3 from 14 million in 2024Q2 representing a change of -1.27%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.0 | 0.0 | -64.34 |
| net income per share | -2.09 | -2.3 | 9.49 |
| operating cash flow per share | -1.51 | -1.54 | 1.66 |
| free cash flow per share | -1.52 | -1.58 | 3.31 |
| cash per share | 2.86 | 7.21 | -60.34 |
| book value per share | 3.26 | 4.65 | -29.83 |
| tangible book value per share | 3.26 | 4.65 | -29.83 |
| shareholders equity per share | 3.26 | 4.65 | -29.83 |
| interest debt per share | 0.61 | 0.66 | -8.78 |
| market cap | 503751007.38 | 900395667.85 | -44.05 |
| enterprise value | 515717007.38 | 419046667.85 | 23.07 |
| pe ratio | -1.54 | -2.73 | 43.62 |
| price to sales ratio | 5302.64 | 3705.33 | 43.11 |
| pocfratio | -2.12 | -4.08 | 48.10 |
| pfcf ratio | -2.11 | -3.99 | 47.22 |
| pb ratio | 0.98 | 1.35 | -27.27 |
| ptb ratio | 0.98 | 1.35 | -27.27 |
| ev to sales | 5428.6 | 1724.47 | 214.80 |
| enterprise value over ebitda | -1.72 | -1.3 | -31.65 |
| ev to operating cash flow | -2.17 | -1.9 | -14.16 |
| ev to free cash flow | -2.16 | -1.86 | -16.10 |
| earnings yield | -0.65 | -0.37 | -77.36 |
| free cash flow yield | -0.47 | -0.25 | -89.46 |
| debt to equity | 0.19 | 0.14 | 29.99 |
| debt to assets | 0.15 | 0.12 | 27.10 |
| net debt to ebitda | -0.04 | 1.5 | -102.66 |
| current ratio | 12.38 | 9.7 | 27.65 |
| interest coverage | 0 | 0 | NaN |
| income quality | 0.73 | 0.66 | 9.57 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 754.45 | 326.36 | 131.17 |
| research and ddevelopement to revenue | 2556.99 | 1055.09 | 142.35 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | -0.02 | 72.91 |
| capex to revenue | 15.96 | 21.36 | -25.30 |
| capex to depreciation | 0.11 | 0.36 | -70.60 |
| stock based compensation to revenue | 694.22 | 344.03 | 101.79 |
| graham number | 12.38 | 15.53 | -20.31 |
| roic | -0.54 | -0.43 | -23.64 |
| return on tangible assets | -0.51 | -0.4 | -26.12 |
| graham net net | 2.03 | 5.93 | -65.84 |
| working capital | 422036000 | 474306000 | -11.02 |
| tangible asset value | 512233000 | 665870000 | -23.07 |
| net current asset value | 328511000 | 377615000 | -13.00 |
| invested capital | 585217000 | 670737000 | -12.75 |
| average receivables | 0 | 0 | NaN |
| average payables | 9893500 | 12072500 | -18.05 |
| average inventory | -31225500 | -41236000 | 24.28 |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 8.86 | 303.08 | -97.08 |
| days of inventory on hand | 0 | -1362.66 | 100.00 |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 41.19 | 1.2 | 3320.42 |
| inventory turnover | 0 | -0.27 | 100.00 |
| roe | -0.64 | -0.5 | -28.99 |
| capex per share | 0.01 | 0.04 | -73.36 |
ROE: Return on Equity (ROE) decreased to -0.64 on 2023-12-31 from -0.50 on 2022-12-31, representing a change of -28.99%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio increased to 12.38 on 2023-12-31 from 9.70 on 2022-12-31, representing a change of 27.65%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -1.54 on 2023-12-31 from -2.73 on 2022-12-31, representing a change of 43.62%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.19 on 2023-12-31 from 0.14 on 2022-12-31, representing a change of 29.99%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| ALLO | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0 | 0 | NaN |
| net income per share | -0.32 | -0.35 | 9.25 |
| operating cash flow per share | -0.21 | -0.33 | 36.98 |
| free cash flow per share | -0.21 | -0.33 | 36.37 |
| cash per share | 1.39 | 2.34 | -40.43 |
| book value per share | 2.22 | 2.71 | -18.21 |
| tangible book value per share | 2.22 | 2.71 | -18.21 |
| shareholders equity per share | 2.22 | 2.71 | -18.21 |
| interest debt per share | 0.41 | 0.5 | -17.81 |
| market cap | 585727942.8 | 442762066.54 | 32.29 |
| enterprise value | 619623942.8 | 366305066.54 | 69.16 |
| pe ratio | -2.21 | -1.67 | -32.42 |
| price to sales ratio | 0 | 0 | NaN |
| pocfratio | -13.28 | -6.96 | -90.68 |
| pfcf ratio | -13.15 | -6.96 | -88.85 |
| pb ratio | 1.26 | 0.86 | 46.92 |
| ptb ratio | 1.26 | 0.86 | 46.92 |
| ev to sales | 0 | 0 | NaN |
| enterprise value over ebitda | -9.84 | -5.83 | -68.65 |
| ev to operating cash flow | -14.05 | -5.76 | -143.82 |
| ev to free cash flow | -13.91 | -5.76 | -141.47 |
| earnings yield | -0.11 | -0.15 | 24.48 |
| free cash flow yield | -0.08 | -0.14 | 47.05 |
| debt to equity | 0.18 | 0.18 | 0.36 |
| debt to assets | 0.14 | 0.15 | -0.77 |
| net debt to ebitda | -0.54 | 1.22 | -144.20 |
| current ratio | 9.35 | 12.25 | -23.73 |
| interest coverage | -717.74 | 0 | NaN |
| income quality | 0.67 | 0.96 | -30.56 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0 | 0 | NaN |
| research and ddevelopement to revenue | 0 | 0 | NaN |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.01 | 0 | NaN |
| capex to revenue | 0 | 0 | NaN |
| capex to depreciation | 0.13 | 0 | NaN |
| stock based compensation to revenue | 0 | 0 | NaN |
| graham number | 3.98 | 4.61 | -13.84 |
| roic | -0.13 | -0.11 | -18.32 |
| return on tangible assets | -0.11 | -0.1 | -9.70 |
| graham net net | 0.79 | 1.65 | -51.73 |
| working capital | 271844000 | 419819000 | -35.25 |
| tangible asset value | 463748000 | 515038000 | -9.96 |
| net current asset value | 179043000 | 325279000 | -44.96 |
| invested capital | 407146000 | 570284000 | -28.61 |
| average receivables | 0 | 0 | NaN |
| average payables | 9221000 | 9357500 | -1.46 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 0 | 0 | NaN |
| days payables outstanding | 0 | 319.5 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 0 | 0 | NaN |
| payables turnover | 0 | 0.28 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.14 | -0.13 | -10.95 |
| capex per share | 0.0 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.14 on 2024-09-30 Q3 from -0.13 on 2024-06-30 Q2, representing a change of -10.95%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -2.21 on 2024-09-30 Q3 from -1.67 on 2024-06-30 Q2, representing a change of -32.42%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio decreased to 9.35 on 2024-09-30 Q3 from 12.25 on 2024-06-30 Q2, representing a change of -23.73%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.18 on 2024-09-30 Q3 from 0.18 on 2024-06-30 Q2, representing a change of 0.36%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is -0.08 which is lower than current price 1.82, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Negative
Publish Date: 2024-12-26 14:10:23
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
Sentiment: Positive
Publish Date: 2024-12-26 13:01:22
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sentiment: Positive
Publish Date: 2024-12-24 08:50:25
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025.
Sentiment: Negative
Publish Date: 2024-12-16 08:30:00
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco.
Sentiment: Negative
Publish Date: 2024-12-12 08:30:00
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today acknowledged the passing of founding board member, David Bonderman. David died at the age of 82, surrounded by his family.
Sentiment: Positive
Publish Date: 2024-12-02 14:20:34
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years.
Sentiment: Positive
Publish Date: 2024-11-25 13:01:23
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sentiment: Negative
Publish Date: 2024-11-19 08:30:00
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed.
Sentiment: Negative
Publish Date: 2024-11-18 08:30:00
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluated as a treatment for autoimmune diseases. The data, presented at the American College of Rheumatology (ACR) Convergence 2024, demonstrate the potential of ALLO-329 to specifically address key challenges associated with current autologous CAR T cell therapies in development for patients with autoimmune disease and highlights the promise of an allogeneic CAR T to reset the immune system.
Sentiment: Negative
Publish Date: 2024-11-08 11:15:20
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.
Sentiment: Positive
Publish Date: 2024-11-07 20:59:01
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - EVP of Research and Development and Chief Medical Officer Geoff Parker - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Luca Issi - RBC Capital Samantha Semenkow - Citi Matthew Biegler - Oppenheimer Brooke Schuster - William Blair William Pickering - Bernstein Laura Prendergast - Raymond James Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call.
Sentiment: Negative
Publish Date: 2024-11-07 16:02:00
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2024.
Sentiment: Positive
Publish Date: 2024-11-07 10:00:00
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, will concurrently present new data from the Phase 1 TRAVERSE trial in an oral presentation at the 2024 International Kidney Cancer Symposium (IKCS) and a poster session at The Society for Immunotherapy of Cancer's (SITC) Annual Meeting. The trial evaluates ALLO-316, the Company's first AlloCAR T product candidate for the potential treatment of solid tumors. The ongoing Phase 1 TRAVERSE trial is enrolling patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed following treatment with an immune checkpoint inhibitor and VEGF-targeting therapy. These presentations highlight compelling evidence of CAR T activity and anti-tumor efficacy in 26 patients with RCC tumors known to be CD70 positive who were evaluable for efficacy outcomes.
Sentiment: Positive
Publish Date: 2024-11-05 09:10:00
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company's first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration's (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.
Sentiment: Negative
Publish Date: 2024-10-31 11:06:22
Allogene Therapeutics (ALLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sentiment: Negative
Publish Date: 2024-10-30 08:30:00
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
